Medical News Podcast PeerDirect

Drs. Claudine Isaacs and Filipa Lynce conclude their discussion on the highlights of ASCO 2024 Annual Meeting, with a focus on HER2+ breast cancer. They discussed results from the Destiny Breast 07 trial, highlighting the efficacy of TDXD alone and in combination with pertuzumab in first-line treatment of HER2-positive breast cancer. The study showed high overall response rates and promising progression-free survival rates with both regimens. ILD was identified as a concerning toxicity. Additionally, an upcoming presentation on the ACE Breast-02 study, which evaluated a novel antibody-drug conjugate against lapatinib and capecitabine in heavily pre-treated HER2-positive patients, was discussed. This novel ADC showed improved progression-free survival compared to the standard regimen but had a different toxicity profile.

Drs. Claudine Isaacs and Filipa Lynce continue their discussion on the highlights of ASCO 2024 Annual Meeting, with a focus on HER2+ breast cancer. In part two of the discussion, the focus is on two studies pertaining to HER2-positive breast cancer. The first study, the GBCRG-M06 Emerald Study compared the effectiveness and toxicity of eribulin mesylate versus a taxane (with trastuzumab and pertuzumab) in a first-line treatment setting. The study, involving approximately 450 patients, found similar progression-free survival (PFS) between the taxane backbone (13 months) and the eribulin backbone (14 months). However, there was slightly more peripheral neuropathy observed with eribulin. The second study discussed is the Patricia study (cohort C) investigating the use of CDK4-6 inhibitors combined with trastuzumab and endocrine therapy in ER-positive, HER2-positive breast cancer patients who had progressed on prior HER2-targeted therapies. The study indicated an improved PFS with the introduction of CDK4-6 inhibitors (9 months) compared to the control arm (7.5 months). The discussion also anticipates the results of the ongoing PATINA study, which looks to determine whether adding CDK4-6 inhibitors during maintenance therapy will benefit patients with advanced ER-positive, HER2-positive breast cancer.

How many patients maintain weight loss 1 year after discontinuing semaglutide or liraglutide? Find out about this and more in today's PeerDirect Medical News Podcast.

Drs. Claudine Isaacs and Filipa Lynce discuss highlights of the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting, with a focus on HER2+ breast cancer, including late-breaking abstracts such as DESTINY‑Breast06 and others.

Which drug keeps lung cancer from progressing for over 5 years? Find out about this and more in today's PeerDirect Medical News Podcast.

Could tattoos be a risk factor for malignant lymphoma? Find out about this and more in today's PeerDirect Medical News Podcast.